| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Outcome Concept Systems is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
VASAMED, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Eden Prairie, MN. To find more information about VASAMED, Inc., please visit www.vasamed.com
Visiting Nurse Association of Tulsa is a Tulsa, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DisperSol Technologies provides expertise in formulation and processing technologies for solubility/bioavailability enhancement of poorly water-soluble drug molecules.